First Gene Therapy for Adults with Severe Hemophilia A, BioMarin s ROCTAVIAN™ (valoctocogene roxaparvovec), Approved by European Commission (EC) apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the European Commission (EC) has granted conditional marketing authorization.
/PRNewswire/ BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the European Commission (EC) has granted conditional marketing authorization.
Fulcrum TherapeuticsAnnounces Second Quarter 2022 Financial Results and Business Update - Presented initial data from Phase 1b trial in sickle cell disease ,. | August 11, 2022
VOXZOGO™ $34 Million Contribution Drives Total Revenues of $534 Million in the Quarter; Total Revenues Grew 13% Year-Over-Year, Excluding Kuvan BioMarin.